Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of BR1019 vs Co-administration of BR1019-2 and BR1019-3
NCT06636877Phase 1Completed
- Sponsor
- Boryung
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fimasartan and dapagliflozin in essential hypertension and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boryung. Primary endpoints: Area under the concentration-time curve from time zero to time tau and Maximum concentration of drug in plasma. Started Oct 2024; status: completed.
02
Drugs
fimasartandapagliflozin
03
Conditions
essential hypertensiontype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06636877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636877.